About Cellumen
Cellumen is a company based in Pittsburgh (United States) founded in 2004 was acquired by Apredica in August 2010. Cellumen has raised $11.43 million across 11 funding rounds from investors including Safeguard Scientifics, Novitas Capital and Apredica. Cellumen offers products and services including Assay Kits, Antibodies, ELISA Kits, Total Protein Assay Kit, and DNA Testing Products. Cellumen operates in a competitive market with competitors including Aganitha, PointCross, IOTA Pharma, Emergentec and Growdea Technologies, among others.
- Headquarter Pittsburgh, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$11.43 M (USD)
in 11 rounds
-
Latest Funding Round
$248.45 K (USD), Series B
Mar 03, 2010
-
Investors
Safeguard Scientifics
& 2 more
-
Employee Count
Not available
-
Acquired by
Apredica
(Aug 05, 2010)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Cellumen
Cellumen offers a comprehensive portfolio of products and services, including Assay Kits, Antibodies, ELISA Kits, Total Protein Assay Kit, and DNA Testing Products.
Kits for detecting biomolecules in biological samples
Proteins used for identifying specific antigens in research
Kits for enzyme-linked assays in protein detection
Kit for quantifying proteins in serum and tissues
Products for DNA analysis and templates in experiments
Funding Insights of Cellumen
Cellumen has successfully raised a total of $11.43M across 11 strategic funding rounds. The most recent funding activity was a Series B round of $248.45 thousand completed in March 2010. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Cellumen
Cellumen has secured backing from 3 investors, including venture fund investors. Prominent investors backing the company include Safeguard Scientifics, Novitas Capital and Apredica.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Venture capital firm investing in early and growth stage companies
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Content on research ethics is shared by Apredica.
|
Locked | Locked | Locked |
Investor details for Cellumen
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Cellumen
Investment portfolio details for Cellumen
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Cellumen
Detailed financials for Cellumen
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Cellumen Comparisons
Peer comparison for Cellumen
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Cellumen
Cellumen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Aganitha, PointCross, IOTA Pharma, Emergentec and Growdea Technologies, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Provider of AI-powered drug discovery and development solutions
|
|
| Locked | Locked | Locked |
Big data platform & desktop software for preclinical & clinical research & regulatory applications
|
|
| Locked | Locked | Locked |
Offers fragment-based drug discovery products and services.
|
|
| Locked | Locked | Locked |
Computational solutions and consulting for better decision making in biomarker, target and drug development.
|
|
| Locked | Locked | Locked |
Offers AI and machine learning for in-silico drug discovery and bioinformatics services.
|
Detailed competitors of Cellumen
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Cellumen
Complete news archive for Cellumen
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Cellumen
Cellumen was founded in 2004.
Cellumen is headquartered in Pittsburgh, United States. It is registered at Pittsburgh, Pennsylvania, United States.
Cellumen is a funded company, having raised a total of $11.43M across 11 funding rounds to date.
Cellumen, acquired by Cyprotex (formerly Apredica) in 2010, was a company offering proprietary cellular systems biology-based solutions for in vitro discovery and toxicology testing of drug candidates. The company had IP w.r.t reagents and multiplexed assays using the High Content Screening platform. The company offered drug discovery and toxicology screening services and was working with immortalised HepG2 human cell lines, primary rat hepatocytes and cardiac cell lines. At the core of Cellumens expertise was its CellCiphr toxicity risk assessment technology. The company had developed CellCiphr profiles by screening a library of compounds and characterising them. These were used to identify and screen potentially toxic compounds at a much earlier stage in the drug discovery process. The company claimed that it could demonstrate savings of up to USD 91Myear for any big pharma company by applying their CellCiphr filter at the start of the hit-to-lead phase.
Cellumen's top competitors include Aganitha, PointCross and Emergentec.
Cellumen offers Assay Kits, Antibodies, ELISA Kits, Total Protein Assay Kit, and DNA Testing Products.
Cellumen has 3 investors. Key investors include Safeguard Scientifics, Novitas Capital, and Apredica.